Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
Portfolio Pulse from
Vaxart, Inc. has initiated a Phase 1 clinical trial for its second-generation oral norovirus vaccine, with topline data expected by mid-2025.
March 11, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart, Inc. has started a Phase 1 trial for its new oral norovirus vaccine, with results expected by mid-2025. This development could influence VXRT's stock price as it progresses.
The initiation of a clinical trial for a new vaccine candidate is a significant milestone for a biotech company like Vaxart. Positive trial results could lead to increased investor interest and a potential rise in stock price. The expectation of topline data by mid-2025 provides a timeline for investors to watch.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100